MX2022009836A - Vacuna para sars-cov-2. - Google Patents
Vacuna para sars-cov-2.Info
- Publication number
- MX2022009836A MX2022009836A MX2022009836A MX2022009836A MX2022009836A MX 2022009836 A MX2022009836 A MX 2022009836A MX 2022009836 A MX2022009836 A MX 2022009836A MX 2022009836 A MX2022009836 A MX 2022009836A MX 2022009836 A MX2022009836 A MX 2022009836A
- Authority
- MX
- Mexico
- Prior art keywords
- cov
- sars
- vaccine
- subject
- nucleic acid
- Prior art date
Links
- 229940022962 COVID-19 vaccine Drugs 0.000 title 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000013638 trimer Substances 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen trímeros de ectodominio S de SARS-CoV-2 estabilizados en una conformación de prefusión, moléculas de ácido nucleico y vectores que codifican estas proteínas, y métodos de su uso y producción. En varias modalidades, los trímeros de ectodominio S de SARS-CoV-2 y/o moléculas de ácido nucleico se pueden utilizar para generar una respuesta inmune a S de SARS-CoV-2 en un sujeto, por ejemplo, una respuesta inmune que inhibe la infección de SARS-CoV-2 en el sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062972886P | 2020-02-11 | 2020-02-11 | |
PCT/US2021/017709 WO2021163365A1 (en) | 2020-02-11 | 2021-02-11 | Sars-cov-2 vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009836A true MX2022009836A (es) | 2022-11-30 |
Family
ID=74860458
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009836A MX2022009836A (es) | 2020-02-11 | 2021-02-11 | Vacuna para sars-cov-2. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230113170A1 (es) |
EP (1) | EP4103229A1 (es) |
JP (1) | JP2023513693A (es) |
KR (1) | KR20220140586A (es) |
CN (1) | CN115515627A (es) |
AU (1) | AU2021221127A1 (es) |
BR (1) | BR112022015628A2 (es) |
CA (1) | CA3170322A1 (es) |
IL (1) | IL295301A (es) |
MX (1) | MX2022009836A (es) |
WO (1) | WO2021163365A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
BR112022019781A2 (pt) * | 2020-04-22 | 2022-12-13 | BioNTech SE | Vacina para o coronavírus |
WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
US20240156946A1 (en) | 2020-12-22 | 2024-05-16 | CureVac SE | Rna vaccine against sars-cov-2 variants |
CN113633764B (zh) * | 2021-09-02 | 2024-05-14 | 中国食品药品检定研究院 | 一种含佐剂的新冠dna疫苗 |
CN113527522B (zh) * | 2021-09-13 | 2021-12-21 | 深圳市瑞吉生物科技有限公司 | 一种新冠病毒三聚体重组蛋白、DNA、mRNA及应用和mRNA疫苗 |
WO2023047348A1 (en) * | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
WO2023047349A1 (en) * | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
CA3234578A1 (en) | 2021-10-22 | 2023-04-27 | Advait Vijay Badkar | Compositions for administration of different doses of rna |
WO2023089556A1 (en) | 2021-11-22 | 2023-05-25 | Pfizer Inc. | Reducing risk of antigen mimicry in immunogenic medicaments |
JP2023081859A (ja) | 2021-11-29 | 2023-06-13 | ビオンテック・ソシエタス・エウロパエア | コロナウイルスワクチン |
WO2023094885A2 (en) * | 2021-11-29 | 2023-06-01 | Arabian Gulf University | Antigenic determinants, protective immunity, serodiagnostic and multivalent subunits precision vaccine against sars-cov-2 |
CN114989308B (zh) * | 2022-05-12 | 2023-04-04 | 中国科学院微生物研究所 | 新冠病毒嵌合核酸疫苗及其用途 |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
CN115287265B (zh) * | 2022-07-12 | 2023-05-23 | 四川大学华西医院 | 多能活性制剂诱发恒河猴抵抗新冠突变体的免疫防治模型 |
WO2024086575A1 (en) | 2022-10-17 | 2024-04-25 | BioNTech SE | Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
CA2142007C (en) | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
EP0667912B1 (fr) | 1993-07-13 | 2008-07-02 | Centelion | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
WO1995016772A1 (en) | 1993-12-14 | 1995-06-22 | Cornell Research Foundation, Inc. | Adenovirus gene expression system |
JP3816518B2 (ja) | 1994-06-10 | 2006-08-30 | ジェンベク、インコーポレイティッド | 相補的なアデノウイルスベクター系と細胞系 |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
WO2003022311A1 (en) | 2001-09-13 | 2003-03-20 | Genvec, Inc. | Adenoviral vector and related system and methods of making and use |
EP3532095A1 (en) * | 2016-10-25 | 2019-09-04 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Prefusion coronavirus spike proteins and their use |
-
2021
- 2021-02-11 JP JP2022548435A patent/JP2023513693A/ja active Pending
- 2021-02-11 CA CA3170322A patent/CA3170322A1/en active Pending
- 2021-02-11 KR KR1020227031250A patent/KR20220140586A/ko unknown
- 2021-02-11 AU AU2021221127A patent/AU2021221127A1/en active Pending
- 2021-02-11 EP EP21710716.8A patent/EP4103229A1/en active Pending
- 2021-02-11 CN CN202180027866.XA patent/CN115515627A/zh active Pending
- 2021-02-11 BR BR112022015628A patent/BR112022015628A2/pt unknown
- 2021-02-11 WO PCT/US2021/017709 patent/WO2021163365A1/en active Application Filing
- 2021-02-11 IL IL295301A patent/IL295301A/en unknown
- 2021-02-11 MX MX2022009836A patent/MX2022009836A/es unknown
- 2021-02-11 US US17/798,021 patent/US20230113170A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230113170A1 (en) | 2023-04-13 |
AU2021221127A1 (en) | 2022-09-22 |
CN115515627A (zh) | 2022-12-23 |
JP2023513693A (ja) | 2023-04-03 |
KR20220140586A (ko) | 2022-10-18 |
IL295301A (en) | 2022-10-01 |
WO2021163365A1 (en) | 2021-08-19 |
EP4103229A1 (en) | 2022-12-21 |
BR112022015628A2 (pt) | 2022-09-27 |
CA3170322A1 (en) | 2021-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009836A (es) | Vacuna para sars-cov-2. | |
WO2016037154A8 (en) | Recombinant hiv-1 envelope proteins and their use | |
MX2021010519A (es) | Proteinas f de rsv de prefusion y su uso. | |
MX2022003994A (es) | Produccion de oligosacaridos de leche humana en huespedes microbianos con importacion/exportacion dise?ada. | |
MX2023008626A (es) | Proteinas klotho recombinantes terapeuticas y composiciones y metodos que involucran a las mismas. | |
BR112018070323A2 (pt) | vacina contra rsv | |
PH12018501047A1 (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
MX2018001567A (es) | Novedosos polipeptidos de fusion especificos para lag-3 y pd-1. | |
MX352974B (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
EA201891945A2 (ru) | Вакцина рекомбинантного модифицированного вируса осповакцины анкара (mva) респираторно-синцитиального вируса (rsv) | |
EP4234027A3 (en) | Prefusion piv f immunogens and their use | |
IN2014DN09351A (es) | ||
WO2021222639A3 (en) | Recombinant human metapneumovirus f proteins and their use | |
MX2014012234A (es) | Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas. | |
EP4272750A3 (en) | Protein antigens that provide protection against pneumococcal colonization and/or disease | |
BR112018010639A2 (pt) | método de transfecção transitória para produção retroviral. | |
MX2020001282A (es) | Polipeptidos que tienen actividad trehalasa y uso de los mismos en proceso de produccion de productos de fermentacion. | |
MY169049A (en) | Microorganisms for producing putrescine and process for producing putrescine using them | |
MX2017013174A (es) | Fusiones de variante iii del receptor de factor de crecimiento epidermico-mesotelina y métodos para usar los mismos. | |
NZ712713A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
CN106687579A8 (zh) | 产生二胺的微生物和使用该微生物产生二胺的方法 | |
MY181148A (en) | Microorganisms for producing diamine and process for producing diamine using them | |
BR112022011422A2 (pt) | Imunógenos para vírus da caxumba e do sarampo e seus usos | |
PH12020551876A1 (en) | Nucleic acid for treating mite allergy |